Medical Condition News

RSS

Bill to stop under 18s using sunbeds passed by the House of Lords

The private member's bill to protect children and teenagers from the dangers of sunbeds was passed today by the House of Lords after Cancer Research UK's campaign.

9 Apr 2010

Abraxis BioScience to present updated survival findings from ABRAXANE Phase I/II trial at 101st AACR meeting

Abraxis BioScience, Inc., a fully integrated biotechnology company, announced that the updated survival findings from a Phase I/II clinical trial evaluating the chemotherapy agent ABRAXANE® for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in combination with gemcitabine for first-line treatment of patients with metastatic pancreatic cancer will be discussed during a keynote address on April 20 at the 101st Annual Meeting of the American Association for Cancer Research (AACR) being held in Washington, D.C.

9 Apr 2010

As overall cancer rates decline in the U.S., thyroid cancer counters the trend

As overall cancer rates are declining in the United States, thyroid cancer counters the trend. It's being diagnosed more frequently, especially in women. Women are three times more likely than men to develop thyroid cancer.

9 Apr 2010

Idera Pharmaceuticals' TLR antagonists exert anti atherogenic effects in preclinical model of atherosclerosis

Idera Pharmaceuticals, Inc. today presented data from a preclinical study evaluating the mechanism of action of a Toll-like Receptor (TLR) antagonist in a preclinical model of atherosclerosis. The presentation entitled "A novel antagonist of TLR7 and TLR9 exerts anti atherogenic effects in ApoE-/- mouse model of atherosclerosis" (abstract P259) was made by Idera scientists at the American Heart Association conference "Arteriosclerosis, Thrombosis and Vascular Biology 2010 Scientific Sessions" being held April 8-10 in San Francisco, CA.

9 Apr 2010

Encouraging results from CCT's Phase I study of PDA-001 for treatment-resistant Crohn's Disease

Celgene Cellular Therapeutics, a wholly owned subsidiary of Celgene Corporation, today announced initial results from a Phase I multicenter safety study of PDA-001 in treatment-resistant Crohn's Disease. PDA-001 is an immunomodulatory therapy consisting of human placenta-derived cells obtained from CCT's proprietary processes.

9 Apr 2010

Dangerous agitations: Nicotine replacement therapy needs to be tested in ICU setting

Nicotine withdrawal can cause dangerous agitation in intensive care patients. Researchers writing in BioMed Central's open access journal Critical Care found that, compared to non-smokers, agitated smokers were more likely to accidentally remove tubes and catheters, require supplemental sedative, analgesic or anti-psychotic medications, or need physical restraints.

9 Apr 2010

Russia's first implant of SynCardia temporary CardioWest Total Artificial Heart performed on 60-year-old female

On March 23, the Bakoulev Scientific Center for Cardiovascular Surgery (BSCCS) in Moscow performed Russia's first implant of the SynCardia temporary CardioWest™ Total Artificial Heart. The patient, a 60-year-old female suffering from biventricular heart failure, is the world's 850th recipient of the Total Artificial Heart.

9 Apr 2010

Sanofi-Aventis acquires exclusive global rights to CureDM's Pancreate

CureDM, LLC announced today that an agreement has been signed with Sanofi-Aventis for the exclusive worldwide license of Pancreate™, a novel islet neogenesis agent for the treatment of type 1 and type 2 diabetes. CureDM is a privately held biopharmaceutical company whose scientists discovered Pancreate™, a first-in-class human peptide therapeutic. Several key Composition of Matter and Use patents have been issued to CureDM for this potentially transforming treatment approach for diabetes.

9 Apr 2010

Keryx Biopharmaceuticals commences Phase 3 registration clinical trial for perifosine

Keryx Biopharmaceuticals, Inc. announced today the initiation of a Phase 3 registration clinical trial for KRX-0401 (perifosine), the Company's novel, potentially first-in-class, oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase (PI3K) pathway, for the treatment of patients with refractory advanced colorectal cancer.

9 Apr 2010

University of Southampton, Synairgen Research scientists commence Phase II trial of interferon beta for asthma

Scientists from the University of Southampton and Synairgen Research Ltd, a respiratory drug development company spun out from the University, have begun a Phase II study into the effectiveness of the drug interferon beta for asthma patients.

9 Apr 2010

Cell Therapeutics receives FDA Complete Response Letter for Pixuvri NDA

Cell Therapeutics, Inc. today announced that it had received a Complete Response Letter from the U.S. Food and Drug Administration regarding its New Drug Application for Pixuvri™ (pixantrone dimaleate) for relapsed or refractory aggressive non-Hodgkin's lymphoma ("NHL").

9 Apr 2010

ReVision Optics initiates US clinical trial of PresbyLens corneal inlay

ReVision Optics, a leading company in the research, development and manufacture of custom optical products to correct and maintain vision, announced today that it has begun its US clinical trial of the PresbyLens® corneal inlay. The clinical trial will evaluate the PresbyLens® corneal inlay for the correction of presbyopia, the age-related loss of near vision. The study began on April 6th with the treatment of three subjects by clinical investigator Dr. Stephen Slade of the Slade & Baker Vision Center in Houston, Texas.

9 Apr 2010

Æterna Zentaris commences perifosine Phase 3 registration trial

Æterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrine therapy, today announced the initiation of a Phase 3 registration clinical trial with perifosine (KRX-0401) ), the Company's novel, potentially first-in-class, oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase (PI3K) pathway, for the treatment of refractory advanced colorectal cancer.

9 Apr 2010

Raised levels of carbon dioxide in blood may lead to ‘near death experiences’

Near death experiences (NDEs), reported to include sensations such as life flashing before the eyes, feelings of peace and joy, and apparent encounters with mystical entities, may be caused by raised levels of carbon dioxide in the blood. Researchers writing in BioMed Central's open access journal Critical Care investigated the unexplained events in 52 cardiac arrest patients.

8 Apr 2010

WTC FDNY Rescue Workers have not recovered normal lung function, yet

A study of nearly 13,000 rescue workers from the Fire Department of the City of New York (FDNY) shows that the significant proportion who suffered acute lung damage after exposure to World Trade Center (WTC) dust have not recovered normal lung function in the years since the September 11, 2001 terrorist attacks.

8 Apr 2010

Dealing with emotional impacts of bullying before it's too late

The California Association of Marriage and Family Therapists (CAMFT) encourages parents to talk with teens about bullying before it's too late. A conversation can be an important first step in identifying a bullying problem and stopping the abuse before it goes too far.

8 Apr 2010

Whey Protein Isolate damages and accelerates hair loss

Dr. Larry Shapiro, a nationally recognized hair transplant surgeon and dermatologist in South Florida, announced today the results of a study that compared the Effects of Whey Protein Concentrate (WPC) to Whey Protein Isolate (WPI) on Hair, which suggests that WPI, an ingredient found in many popular weight loss, meal replacement and body building products, is contributing to hair loss.

8 Apr 2010

Crohn's disease: Remicade prescription to decrease, while Humira's increases

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed gastroenterologists estimate that (assuming no new data on adverse events emerge) they will treat fewer Crohn's disease patients with Centocor Ortho Biotech/Merck/Mitsubishi Tanabe's Remicade by the end of 2010, while the percentage of biologics-treated patients receiving Abbott/Eisai's Humira will increase to 36 percent.

8 Apr 2010

Combining antiangiogenic cancer therapy with oncolytic virotherapy leads to regression of tumors

Oncolytics Biotech Inc. announced today that a paper entitled "Antiangiogenic cancer therapy combined with oncolytic virotherapy leads to regression of established tumors in mice," co-senior authored by Dr. Richard Vile of the Department of Immunology, Mayo Clinic, Rochester, Minnesota, USA, and Dr. Kevin Harrington of the Institute of Cancer Research, London, UK, was published in the online version of the Journal of Clinical Investigation on April 1, 2010.

8 Apr 2010

Obese patients may receive higher rate of recommended care than normal-weight patients, but not lower

Despite a concern that obese or overweight patients may receive lower quality of health care, an analysis of eight common outpatient quality measures from a sample of nearly 70,000 patients finds no evidence that obese or overweight patients receive inferior care when compared with normal-weight patients, and in fact may receive a higher rate of recommended care on several measures, according to a study in the April 7 issue of JAMA.

8 Apr 2010

Medical Condition News

Bill to stop under 18s using sunbeds passed by the House of Lords

Abraxis BioScience to present updated survival findings from ABRAXANE Phase I/II trial at 101st AACR meeting

As overall cancer rates decline in the U.S., thyroid cancer counters the trend

Idera Pharmaceuticals' TLR antagonists exert anti atherogenic effects in preclinical model of atherosclerosis

Encouraging results from CCT's Phase I study of PDA-001 for treatment-resistant Crohn's Disease

Dangerous agitations: Nicotine replacement therapy needs to be tested in ICU setting

Russia's first implant of SynCardia temporary CardioWest Total Artificial Heart performed on 60-year-old female

Sanofi-Aventis acquires exclusive global rights to CureDM's Pancreate

Keryx Biopharmaceuticals commences Phase 3 registration clinical trial for perifosine

University of Southampton, Synairgen Research scientists commence Phase II trial of interferon beta for asthma

Cell Therapeutics receives FDA Complete Response Letter for Pixuvri NDA

ReVision Optics initiates US clinical trial of PresbyLens corneal inlay

Æterna Zentaris commences perifosine Phase 3 registration trial

Raised levels of carbon dioxide in blood may lead to ‘near death experiences’

WTC FDNY Rescue Workers have not recovered normal lung function, yet

Dealing with emotional impacts of bullying before it's too late

Whey Protein Isolate damages and accelerates hair loss

Crohn's disease: Remicade prescription to decrease, while Humira's increases

Combining antiangiogenic cancer therapy with oncolytic virotherapy leads to regression of tumors

Obese patients may receive higher rate of recommended care than normal-weight patients, but not lower

How can microdialysis benefit drug development

Global and Local Efforts to Take Action Against Hepatitis

Addressing Important Cardiac Biology Questions with Shotgun Top-Down Proteomics

Latest News